Incyte shares tumble after FDA requires new Phase II

Shares of Incyte tumbled 30 percent in early trading today after the company acknowledged that the FDA has asked it to mount a new mid-stage trial of its HIV drug Reverset. The agency wants more data on the drug's safety and efficacy in treating HIV patients who had already received other treatments. That will delay two Phase III trials and push back any potential market launch.

- read this story from MarketWatch for more

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.